Related Experiment Videos
Diabetic hypoglycaemia
1Clinical Sciences Centre, Northern General Hospital, Sheffield, UK.
Abstract:
Hypoglycaemia is a major factor preventing insulin-treated patients from achieving normoglycaemia. This reflects the inadequacy of current insulin treatment, which causes high insulin concentrations in the post-absorptive period. Physiological defences to hypoglycaemia include autonomic activation, which limits the fall in glucose level and causes symptoms, alerting patients to an impending episode. Many patients develop defective responses and hypoglycaemia unawareness after longstanding disease or with tight glycaemic control and are then prone to severe attacks. This may be the result of repeated hypoglycaemic episodes, which by altering cerebral glucose uptake, disturb the mechanisms that activate the central response to hypoglycaemia. Preventing further hypoglycaemia can partially reverse these defects and restore symptomatic awareness. Clinical hypoglycaemia has also been implicated in the 'dead in bed' syndrome and in chronic cognitive impairment. The problem of hypoglycaemia will eventually be solved by better insulin delivery and non-invasive glucose meters, but until then, more focused education may have a more substantial impact.
Insights
Hypoglycaemia, or low blood sugar, hinders diabetes management in insulin-treated patients. Addressing defective responses and unawareness through education is crucial until better insulin therapies emerge.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Hypoglycaemia (low blood glucose) is a significant barrier to achieving normoglycaemia in patients treated with insulin.
- Current insulin therapies often lead to supra-physiological post-absorptive insulin levels, contributing to hypoglycaemia.
- Physiological counter-regulatory responses, including autonomic activation, normally protect against falling glucose levels and provide warning symptoms.
Purpose of the Study:
- To examine the impact of hypoglycaemia on insulin-treated patients.
- To understand the mechanisms behind defective hypoglycaemia responses and unawareness.
- To explore potential interventions for managing hypoglycaemia and its consequences.
Main Methods:
- Review of physiological defence mechanisms against hypoglycaemia.
- Analysis of factors contributing to defective autonomic responses and hypoglycaemia unawareness.
- Discussion of the implications of recurrent hypoglycaemia on cognitive function and mortality.
- Consideration of future technological advancements in glucose monitoring and insulin delivery.
Main Results:
- Patients on insulin often experience hypoglycaemia due to treatment limitations.
- Longstanding diabetes or intensive glycaemic control can impair the body's response to low blood sugar.
- Repeated hypoglycaemic episodes can lead to impaired cerebral glucose uptake and loss of warning symptoms.
- Preventing further hypoglycaemia can partially restore defective responses and symptomatic awareness.
Conclusions:
- Hypoglycaemia remains a critical challenge in insulin therapy, impacting patient safety and quality of life.
- Defective counter-regulation and unawareness of hypoglycaemia can result from disease duration and treatment intensity.
- Clinical hypoglycaemia is linked to adverse outcomes like 'dead in bed' syndrome and cognitive impairment.
- While technological solutions are forthcoming, enhanced patient education is vital for mitigating hypoglycaemia risks.